2024
Factor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease.
Allen C, Heskel M, Butt A, Tormey C, Pine A, Lee A, Gautam S. Factor VIII Levels and ISTH Disseminated Intravascular Coagulation Scores Do Not Distinguish Disseminated Intravascular Coagulation from the Coagulopathy of Liver Disease. Acta Haematologica 2024, 1-5. PMID: 39004080, DOI: 10.1159/000540239.Peer-Reviewed Original ResearchISTH DIC scoreFactor VIII levelsArea under the curveDIC scoreLiver diseaseFactor VIIIRetrospective chart review of patientsChart review of patientsCoagulopathy of liver diseaseReview of patientsRetrospective chart reviewCalculate area under the curveReceiver operating characteristic curveMultiple logistic regressionISTH scoreLaboratory parametersClinical challengeClinical utilityPatientsCharacteristic curveLab variablesLogistic regressionLiverDiseaseDiagnostic tool
2023
Comprehensive Characterization of Coagulation Parameters in Venous Malformations
Restrepo V, Pine A, Butt A, Chang E, Bar N, Baluha A, Brooks A, Chirico G, Curran J, Dumont A, Obura-Wilkes P, Rinder H, Tormey C, Nassiri N, Lee A, Prozora S. Comprehensive Characterization of Coagulation Parameters in Venous Malformations. Blood 2023, 142: 27. DOI: 10.1182/blood-2023-190609.Peer-Reviewed Original ResearchHigher thrombin-antithrombin complexesNormal D-dimerThrombin-antithrombin complexPlasminogen activator inhibitor-1Localized intravascular coagulopathyInternational normalized ratioD-dimerVenous malformationsCoagulation parametersPartial thromboplastin timeCoagulation testsFactor VIIIVWF activityChart reviewMost patientsHematology clinicProthrombin timeTissue involvementVWF antigenVon Willebrand factor antigenHigher TAT levelsMultiple coagulation parametersBaseline patient characteristicsRetrospective chart reviewCoagulation test results
2022
Association of iron infusion reactions with ABO blood type
Butt A, Muradashvili T, Soliman S, Li F, Burns AJ, Brooks A, Browning S, Bar N, Borgman G, Goshua G, Hwa J, Martin K, Rinder H, Tormey C, Pine AB, Bona RD, Lee AI, Neparidze N. Association of iron infusion reactions with ABO blood type. European Journal Of Haematology 2022, 109: 519-525. PMID: 35871468, DOI: 10.1111/ejh.13838.Peer-Reviewed Original ResearchConceptsGreater oddsBlood typeYale Cancer CenterInfusion-related reactionsRetrospective chart reviewLarger patient numbersABO blood typeType AB bloodChart reviewInfusion reactionsMost patientsHematology clinicIron sucroseMultivariable analysisProspective studyCancer CenterPatient numbersIron dextranRisk factorsIron infusionIron repletionPatientsPossible associationAB bloodBlood
2021
Iron Infusion Reactions: Risk Factors and Real-World Experience
Butt A, Muradashvili T, Soliman S, Goshua G, Burns A, Bar N, Martin K, Borgman G, Bona R, Lee A, Neparidze N. Iron Infusion Reactions: Risk Factors and Real-World Experience. Blood 2021, 138: 4154. DOI: 10.1182/blood-2021-151048.Peer-Reviewed Original ResearchInfusion-related reactionsSeverity of IRRsHistory of CVDHistory of allergyCardiovascular diseaseBeta blockersOral ironPatient characteristicsRisk factorsLower oddsGreater oddsExact testAngiotensin-converting enzyme inhibitor useAssociation of CVDYale-New Haven HospitalEnzyme inhibitor useFirst-line therapyHeavy menstrual bleedingRetrospective chart reviewMajority of patientsAnti-inflammatory effectsMajor adverse effectsIron deficiency anemiaMultivariable regression analysisSeverity of reactions
2018
Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns
Effendi M, Stutsky M, Curran C, Owusu K, Lee A. Impact of a Pharmacist Driven Anti-Xa Level Monitoring Protocol on Therapeutic Drug Monitoring Practice Patterns. Blood 2018, 132: 2284. DOI: 10.1182/blood-2018-99-119379.Peer-Reviewed Original ResearchLow molecular weight heparinAnti-Xa levelsAnti-Xa level monitoringRetrospective chart reviewNon-therapeutic levelsEnoxaparin doseAdult patientsChart reviewCommon indicationDose adjustmentNursing staffBody weightDrug monitoringTherapeutic monitoringAbnormal levelsStudy periodExtreme body weightRoutine laboratory monitoringRenal replacement therapyCertain patient populationsMolecular weight heparinFavorable pharmacokinetic profileRisk of toxicityClinical decision makingEnoxaparin therapy
2015
Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy
Stutsky M, Reardon D, Lee A. Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy. Blood 2015, 126: 3275. DOI: 10.1182/blood.v126.23.3275.3275.Peer-Reviewed Original ResearchAnti-Xa levelsAnti-Xa monitoringLMWH doseLow molecular weight heparin therapyAbnormal body mass indexActions of providersWeight heparin therapyAcute kidney injuryChronic kidney diseaseHigh-risk patientsRetrospective chart reviewLong-term therapyBody mass indexClinical practice patternsFactor Xa inhibitorsNon-therapeutic levelsEnoxaparin doseHematology consultHeparin regimensTherapeutic LMWHHeparin therapyKidney injuryLMWH therapyRenal dysfunctionVenous thromboembolism